The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
ID: ALA204446
Max Phase: Preclinical
Molecular Formula: C18H24N8OS
Molecular Weight: 400.51
Molecule Type: Small molecule
Associated Items:
Representations Canonical SMILES: N#Cc1cnc(Nc2cc(N3CCN(CCN4CCOCC4)CC3)ncn2)s1
Standard InChI: InChI=1S/C18H24N8OS/c19-12-15-13-20-18(28-15)23-16-11-17(22-14-21-16)26-5-3-24(4-6-26)1-2-25-7-9-27-10-8-25/h11,13-14H,1-10H2,(H,20,21,22,23)
Standard InChI Key: YOARXMDDBVYHOA-UHFFFAOYSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Properties Molecular Weight: 400.51Molecular Weight (Monoisotopic): 400.1794AlogP: 1.00#Rotatable Bonds: 6Polar Surface Area: 93.44Molecular Species: NEUTRALHBA: 10HBD: 1#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 0CX Acidic pKa: 8.27CX Basic pKa: 7.28CX LogP: 1.52CX LogD: 1.47Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.76Np Likeness Score: -2.10
References 1. Sisko JT, Tucker TJ, Bilodeau MT, Buser CA, Ciecko PA, Coll KE, Fernandes C, Gibbs JB, Koester TJ, Kohl N, Lynch JJ, Mao X, McLoughlin D, Miller-Stein CM, Rodman LD, Rickert KW, Sepp-Lorenzino L, Shipman JM, Thomas KA, Wong BK, Hartman GD.. (2006) Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase., 16 (5): [PMID:16368234 ] [10.1016/j.bmcl.2005.11.089 ]